Site-directed modification of FVIII

Details Site-directed modification of FVIII Site-directed modification of FVIII

2005-11-14

2009-12-15

Steadman, David J (Department: 1656)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C435S070100

Reexamination Certificate

active

07632921

ABSTRACT:
This invention relates to Factor VIII muteins that are covalently bound, at one or more predefined sites that are not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity, are capable of correcting human factor VIII deficiencies and have improved pharmacokinetic properties.

REFERENCES:
patent: 4970300 (1990-11-01), Fulton et al.
patent: 5171844 (1992-12-01), van Ooyen et al.
patent: 5422260 (1995-06-01), Kaufman et al.
patent: 5451521 (1995-09-01), Kaufman et al.
patent: 5925739 (1999-07-01), Spira et al.
patent: 5972885 (1999-10-01), Spira et al.
patent: 6048720 (2000-04-01), Dalborg et al.
patent: 6251632 (2001-06-01), Lillicrap et al.
patent: 6316226 (2001-11-01), Van Ooyen et al.
patent: 6346513 (2002-02-01), Van Ooyen et al.
patent: 6753165 (2004-06-01), Cox et al.
patent: 6759216 (2004-07-01), Lollar
patent: 6770744 (2004-08-01), Lollar
patent: 6919311 (2005-07-01), Lenting et al.
patent: 7033791 (2006-04-01), Lollar
patent: 7138505 (2006-11-01), Kuo et al.
patent: 7199223 (2007-04-01), Bossard et al.
patent: 7205278 (2007-04-01), Griffin et al.
patent: 7211559 (2007-05-01), Saenko et
patent: 2002/0182670 (2002-12-01), Lollar
patent: 2003/0077752 (2003-04-01), Cho et al.
patent: 2003/0125232 (2003-07-01), Griffin et al.
patent: 2004/0180054 (2004-09-01), Kim et al.
patent: 2004/0235734 (2004-11-01), Bossard et al.
patent: 2004/0248785 (2004-12-01), Saenko et al.
patent: 2005/0107297 (2005-05-01), Holmes et al.
patent: 2005/0118684 (2005-06-01), Lollar
patent: 2005/0123997 (2005-06-01), Lollar
patent: 2005/0176108 (2005-08-01), Kim et al.
patent: 2005/0256304 (2005-11-01), Jones et al.
patent: 2005/0288490 (2005-12-01), Nakamoto et al.
patent: 2006/0073113 (2006-04-01), Nakamoto et al.
patent: 2006/0160994 (2006-07-01), Lenting et al.
patent: 690126 (1996-01-01), None
patent: 786474 (1997-07-01), None
patent: 808901 (1997-11-01), None
patent: 1502921 (2005-02-01), None
patent: WO-90/12874 (1990-11-01), None
patent: WO-94/15625 (1994-07-01), None
patent: 97/03195 (1997-01-01), None
patent: WO-97/11957 (1997-04-01), None
patent: 00/071714 (2000-11-01), None
patent: 02/096454 (2002-12-01), None
patent: 02/098454 (2002-12-01), None
patent: 03/031598 (2003-04-01), None
patent: WO-2004/075923 (2004-09-01), None
patent: 2005/000360 (2005-01-01), None
patent: 2005/046583 (2005-05-01), None
patent: 2005/055930 (2005-06-01), None
patent: 2006/027111 (2006-03-01), None
patent: 2006/103298 (2006-10-01), None
Rostin et al. (2000) Bioconjugate Chem, vol. 11, 387-396.
Guo et al., Protein tolerance to random amino acid change, (2004) Proc. Natl. Acad. Sci. USA 101: 9205-9210.
Lazar et al., Trnasforming Growth Factor alpha: Mutation of aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, (1988) Mol. Cell. Biol. 8:1247-1252.
Hill et al., Functional Analysis of Conserved Histidines in ADP-Glucose Pyrophosphorylase fromEscherichia coli, (1998) Biochem. Biophys. Res. Comm. 244:573-577.
Sakuragawa, N. et al. Studies on the Stability of Factor VIII Modified by Polyethylene Glycol.Acta Medica et Biologica, 36(1), pp. 1-6 (1988). (Abstract only).
Saenko, E., et al., “Role of the Low Density Lipoprotein-Related Protein Receptor in Mediation of Factor VIII Catabolism”, The Journal of Biological Chemistry, vol. 274, No. 53, 1999, pp. 37685-37692.
Fay, P. J., et al., “Human Factor VIIIaSubunit Structure”, The Journal of Biological Chemistry, vol. 266, No. 14, 1991, pp. 8957-8962.
Bovenschen, N., et al., “Low Density Lipoprotein Receptor-Related Protein and Factor IXa Share Structural Requirements for Binding to the A3 Domain of Coagulation Factor VIII”, The Journal of Biological Chemistry, vol. 278, No. 11, 2003, pp. 9370-9377.
Jacquemin, M., et al., “A Novel Cause of Mild/Moderate Hemophilia A: Mutations Scattered in the Factor VIII C1 Domain Reduce Factor VIII Binding to von Willebrand Factor”, Blood, vol. 96, No. 3, 2000, pp. 958-965.
Barrow, R., et al., “Reduction of the Antigenicity of Factor VIII Toward Complex Inhibitory Antibody Plasmas Using Multiply-Substituted Hybrid Human/Porcine Factor VIII Molecules”, Blood, vol. 95, No. 2, 2000, pp. 564-568.
Regan, L., et al., “Activated Protein C-Catalyzed Proteolysis of Factor Villa Alters Its Interactions Within Factor Xase”, The Journal of Biological Chemistry, vol. 271, No. 8, 1996, pp. 3982-3987.
Lenting, P., et al., “The Light Chain of Factor VIII Comprises a Binding Site for Low Density Lipoprotein Receptor-Related Protein”, The Journal of Biological Chemistry, vol. 274, No. 34, 1999, pp. 23734-23739.
Lenting, P. , et al., “The Sequence Glu1811-Lys1818of Human Blood Coagulation Factor VIII Comprises a Binding Site for Activated Factor IX”, The Journal of Biological Chemistry, vol. 271, No. 4, 1996, pp. 1935-1940.
Lubin, I., et al., “Analysis of the Human Factor VIII A2 Inhibitor Epitope by Alanine Scanning Mutagenesis”, The Journal of Biological Chemistry, vol. 272, No. 48, 1997, pp. 30191-30195.
Gilbert, G., et al., “Four Hydrophobic Amino Acids of the Factor VIII C2 Domain Are Constituents of Both the Membrane-Binding and von Willebrand Factor-Binding Motifs”, The Journal of Biological Chemistry, vol. 277, No. 8, 2002, pp. 6374-6381.
Scandella, D., et al., “Localization of Epitopes for Human Factor VIII Inhibitor Antitodies by Immunoblotting and Antibody Neutralization”, Blood, vol. 74, No. 5, 1989, pp. 1618-1626.
Foster, P., et al., “An Immunogenic Region within Residues Val1670-Glu1684of the Factor VIII Light Chain Induces Antibodies Which Inhibit Binding of Factor VIII to von Willebrand Factor”, The Journal of Biological Chemistry, vol. 263, No. 11, 1988, pp. 5230-5234.
Lubin, I., et al., “Elimination of a Major Inhibitor Epitope in Factor VIII”, The Journal of Biological Chemistry, vol. 269, No. 12, 1994, pp. 8639-8641.
Scandella, D., et al., “A Recombinant Factor VIII A2 Domain Polypeptide Quantitatively Neutralizes Human Inhibitor Antibodies That Bind to A2”, Blood, vol. 82, No. 6, 1993, pp. 1767-1775.
Sarafanov, A., “Cell Surface Heparan Sulfate Proteoglycans Participate in Factor VIII Catabolism Mediated by Low Density Lipoprotein Receptor-Related Protein”, The Journal of Biological Chemistry, vol. 276, No. 15, 2001, pp. 11970-11979.
Parker, E., et al., “Reduction of the Inhibitory Antibody Response to Human Factor VIII in Hemophilia A Mice by Mutagenesis of the A2 Domain B-Cell Epitope”, Blood, vol. 104, No. 3, 2004, pp. 704-710.
Scandella, D., et al., “Epitope Mapping of Human Factor VIII Inhibitor Antibodies by Deletion Analysis of Factor VIII Fragments Expressed inEscherichia coli”, Proc. Natl. Acad. Sci. USA, vol. 85, 1988, pp. 6152-6156.
Nogami, K., et al., “Identification of a Factor Xa-Interactive Site Within Residues 337-372 of the Factor VIII Heavy Chain”, The Journal of Biological Chemistry, vol. 279, No. 16, 2004, pp. 15763-15771.
Pittman, D., et al., “Proteolytic Requirements for Thrombin Activation of Anti-Hemophilic Factor (Factor VIII)”, Proc. Natl. Acad. Sci. USA, vol. 85, 1988, pp. 2429-2433.
Healy, J., et al., “Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII”, The Journal of Biological Chemistry, vol. 270, No. 24, 1995, pp. 14505-14509.
Fulcher, C., et al., “Localization of Human Factor FVIII Inhibitor Epitopes to Two Polypeptide Fragments”, Proc. Natl. Acad. Sci. USA, vol. 82, 1985, pp. 7728-7732.
McMullen, B., et al., “Locations of Disulfide Bonds and Free Cysteines in the Heavy and Light Chains of Recombinant Human Factor VIII (Antihemophilic Factor A)”, Protein Science, vol. 4, 1995, pp. 740-746.
Fay, P. , et al., “Factor VIIIa A2 Subunit Residues 558-565 Represent a Factor IXa Interactive Site”, The Journal of Biological

Affiliated with

Also associated with

Rating

Site-directed modification of FVIII does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Site-directed modification of FVIII, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Site-directed modification of FVIII will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4071599